Latest Administration News

VanEck Investments Limited has announced final dividends for a suite of its Australian and global bond ETFs, with payments scheduled for mid-February 2025. Investors are advised to note the ex-dividend dates and dividend reinvestment plan details.

Many Peaks Minerals has reported significant drilling progress and new high-grade gold targets at its Côte d'Ivoire projects, supported by strong financial backing and strategic leadership appointments.

One Click Group Limited reported a 42% increase in registered users and a 26% rise in revenue to $4.9 million in Q4 2024, while preparing to launch its new superannuation product in 2025.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

TZ Limited reported a quarterly revenue shortfall in Q2 FY2025 due to delayed US projects but anticipates a strong rebound post-election and strategic growth through acquisition.

GreenHy2 Limited reports a slight cash decline but strengthens its foothold in renewable energy with key partnerships and strategic pivots in hydrogen storage technology.

Fluence Corporation Limited reported a net cash outflow of US$3.03 million for the December 2024 quarter, maintaining liquidity with nearly US$9 million in cash and expanded credit facilities.

Gas2Grid navigates regulatory headwinds in Australia by pursuing new petroleum ventures in the Philippines while contesting a significant legal claim in France. The company’s ASX suspension persists as it seeks to restore compliance through fresh contracts.

Beonic's Q2 FY2025 results reveal steady recurring revenue growth and a significant gross margin improvement, underpinning its path to cashflow breakeven. Strategic contract wins and leadership appointments position the company for accelerated IoT adoption.

Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.